UCB SA (OTCMKTS:UCBJF) Stock Now Rated “Moderate Buy” by Sell-Side Analysts

Shares of UCB SA (OTCMKTS:UCBJF) have been given an average rating of “Moderate Buy” by the seven analysts that are covering the stock, MarketBeat reports. Two research analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company.

Several equities analysts recently weighed in on UCBJF shares. Jefferies Financial Group upgraded UCB to a “hold” rating in a research note on Monday, August 3rd. Piper Sandler reaffirmed a “neutral” rating on shares of UCB in a research note on Wednesday, July 22nd.

UCB Trading Down 1.7%

UCBJF stock opened at $232.62 on Monday. UCB has a one year low of $219.60 and a one year high of $345.39. The company has a debt-to-equity ratio of 0.33, a quick ratio of 0.78 and a current ratio of 1.19. The firm’s fifty day moving average is $251.62 and its 200 day moving average is $279.18.

UCB Company Profile

UCB SA is a Belgium-based biopharmaceutical company focused on developing and commercializing medicines for severe diseases, particularly in immunology and neurology. The company’s research and development activities target conditions such as inflammatory disorders, epilepsy, and other diseases affecting the central nervous system.

UCB’s portfolio includes Bimzelx (bimekizumab) for certain inflammatory conditions, Cimzia (certolizumab pegol) for immune-mediated diseases, and Fintepla (fenfluramine), Briviact (brivaracetam), Keppra (levetiracetam), and Nayzilam (midazolam) for seizure-related disorders.